Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2017

01-07-2017 | Epidemiology

Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls

Authors: Ana Elisa Lohmann, Marguerite Ennis, Sara K. Taylor, Pamela J. Goodwin

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Login to get access

Abstract

Purpose

We studied metabolic factors, diabetes, and anthropometric measurements at diagnosis and long-term follow-up (LTFU), mean 12.5 years post-diagnosis, in breast cancer (BC) survivors, and compared their status at LTFU to that of age-matched women without BC. Diet and physical activity were also assessed.

Method

535 non-diabetic BC patients treated at three University of Toronto hospitals were followed prospectively; 285 surviving patients, without distant recurrence, participated in a LTFU study. A control group of 167 age-matched women without BC was recruited from a mammogram screening program at one of the hospitals. Change over time was analyzed using paired t tests, and comparisons between BC survivors and controls used age and education (AE)-adjusted regression models.

Results

Median weight gain in BC survivors was 2.00 kg (p < 0.0001); BMI, glucose, insulin, homeostasis model assessment (HOMA), and total cholesterol increased modestly but significantly. Waist circumference, glucose, and triglycerides were higher in LTFU BC survivors versus controls. BC survivors had significantly greater prevalence of diabetes/pre-diabetes versus controls (33 vs. 20.4%, AE-adjusted odds ratio (OR) 1.59, p = 0.050). This effect was restricted to those with lower levels of physical activity (<56 metabolic equivalent (MET)-hours/week: OR 2.70 versus 0.94 for those with higher physical activity, interaction p = 0.034). At LTFU, BC survivors were more physically active than at diagnosis (median increase 28 MET-hours/week interquartile range −14.8 to 82), and compared to controls (median 68.2 vs. 44 MET-hours/week, p < 0.0001).

Conclusion

The prevalence of the metabolic syndrome and diabetes/pre-diabetes was significantly higher in BC survivors than in controls group, notably in those with lower levels of physical activity. Enhanced diabetes/metabolic syndrome screening and promotion of physical activity may be warranted in BC survivors.
Appendix
Available only for authorised users
Literature
1.
go back to reference NCD Risk Factor Collaboration (NCD-RisC) (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387:1377–1396CrossRef NCD Risk Factor Collaboration (NCD-RisC) (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387:1377–1396CrossRef
2.
go back to reference Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120:1640–1645CrossRefPubMed Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 120:1640–1645CrossRefPubMed
3.
go back to reference Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914CrossRefPubMedPubMedCentral Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901–1914CrossRefPubMedPubMedCentral
4.
go back to reference Dobbins M, Decorby K, Choi BC (2013) The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013:680536CrossRefPubMedPubMedCentral Dobbins M, Decorby K, Choi BC (2013) The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013:680536CrossRefPubMedPubMedCentral
5.
go back to reference Goodwin PJ, Ennis M, Pritchard KI et al (2012) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30:164–171CrossRefPubMed Goodwin PJ, Ennis M, Pritchard KI et al (2012) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30:164–171CrossRefPubMed
6.
go back to reference Bhandari R, Kelley GA, Hartley TA et al (2014) Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int J Breast Cancer 2014:189384CrossRefPubMedPubMedCentral Bhandari R, Kelley GA, Hartley TA et al (2014) Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int J Breast Cancer 2014:189384CrossRefPubMedPubMedCentral
7.
go back to reference Bjorge T, Lukanova A, Jonsson H et al (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 19:1737–1745CrossRefPubMed Bjorge T, Lukanova A, Jonsson H et al (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 19:1737–1745CrossRefPubMed
8.
go back to reference National Institutes of Health (1982) Manual of laboratory operations, lipid research clinics program: lipid and lipoprotein analysis. National Institutes of Health, Bethesda National Institutes of Health (1982) Manual of laboratory operations, lipid research clinics program: lipid and lipoprotein analysis. National Institutes of Health, Bethesda
9.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
10.
go back to reference Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51CrossRefPubMed Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51CrossRefPubMed
11.
go back to reference Farquhar JW, Fortmann SP, Maccoby N et al (1985) The stanford five-city project: design and methods. Am J Epidemiol 122:323–334CrossRefPubMed Farquhar JW, Fortmann SP, Maccoby N et al (1985) The stanford five-city project: design and methods. Am J Epidemiol 122:323–334CrossRefPubMed
12.
go back to reference Sallis JF, Haskell WL, Wood PD et al (1985) Physical activity assessment methodology in the five-city project. Am J Epidemiol 121:91–106CrossRefPubMed Sallis JF, Haskell WL, Wood PD et al (1985) Physical activity assessment methodology in the five-city project. Am J Epidemiol 121:91–106CrossRefPubMed
13.
go back to reference Bonora E, Targher G, Alberiche M et al (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57–63CrossRefPubMed Bonora E, Targher G, Alberiche M et al (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57–63CrossRefPubMed
14.
go back to reference Program National Cholesterol Education (2002) (NCEP) Expert Panel on Detection, Evaluation: third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421 Program National Cholesterol Education (2002) (NCEP) Expert Panel on Detection, Evaluation: third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421
15.
go back to reference Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Diabetes Care 39(Suppl 1):107 Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Diabetes Care 39(Suppl 1):107
16.
go back to reference Lauzier S, Maunsell E, Drolet M et al (2008) Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst 100:321–332CrossRefPubMed Lauzier S, Maunsell E, Drolet M et al (2008) Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst 100:321–332CrossRefPubMed
17.
go back to reference Lipscombe LL, Chan WW, Yun L et al (2013) Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56:476–483CrossRefPubMed Lipscombe LL, Chan WW, Yun L et al (2013) Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56:476–483CrossRefPubMed
18.
go back to reference Bordeleau L, Lipscombe L, Lubinski J et al (2011) Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117:1812–1818CrossRefPubMed Bordeleau L, Lipscombe L, Lubinski J et al (2011) Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117:1812–1818CrossRefPubMed
19.
go back to reference Lipscombe LL, Fischer HD, Yun L et al (2012) Association between tamoxifen treatment and diabetes: a population-based study. Cancer 118:2615–2622CrossRefPubMed Lipscombe LL, Fischer HD, Yun L et al (2012) Association between tamoxifen treatment and diabetes: a population-based study. Cancer 118:2615–2622CrossRefPubMed
20.
go back to reference Hickish T, Astras G, Thomas P et al (2009) Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst 101:537CrossRefPubMed Hickish T, Astras G, Thomas P et al (2009) Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst 101:537CrossRefPubMed
21.
go back to reference Dieli-Conwright CM, Wong L, Waliany S et al (2016) An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 22(17):2646–2653CrossRef Dieli-Conwright CM, Wong L, Waliany S et al (2016) An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. Cancer 22(17):2646–2653CrossRef
Metadata
Title
Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls
Authors
Ana Elisa Lohmann
Marguerite Ennis
Sara K. Taylor
Pamela J. Goodwin
Publication date
01-07-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4263-z

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine